# Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

> **NCT00148070** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **PROCEDURE:** Erythromycin Breath Test (ERMBT)

## Key facts

- **NCT ID:** NCT00148070
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2004-09
- **Final completion:** 2006-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148070, "Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00148070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*